PPARα serves as a new receptor of aspirin for neuroprotection

J Neurosci Res. 2020 Apr;98(4):626-631. doi: 10.1002/jnr.24561. Epub 2019 Dec 3.

Abstract

Acetyl salicylic acid, commonly known as aspirin, has been being widely used as an anti-inflammatory drug for almost 100 years. However, there was no receptor known for this popular drug. Recently, we have established that peroxisome proliferator-activated receptor alpha (PPARα) acts as a novel receptor of aspirin. Activation of PPARα by aspirin stimulated a series of downstream signaling pathways that could potentially ameliorate different Alzheimer's disease (AD)-related pathologies. In this mini-review, we have discussed how aspirin-PPARα interaction plays a pivotal role in the amelioration of AD pathology via the stimulation of neurotrophic factors, upregulation of plasticity-associated genes, and removal of plaque burden in hippocampal neurons.

Keywords: Alzheimer's disease; BDNF; PPARα; calcium influx; hippocampal plasticity; spine density.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Alzheimer Disease / drug therapy*
  • Animals
  • Aspirin / administration & dosage*
  • Brain / drug effects
  • Brain / physiopathology*
  • Humans
  • Neuronal Plasticity / drug effects
  • Neurons / drug effects
  • Neurons / physiology
  • Neuroprotective Agents / administration & dosage*
  • PPAR alpha / pharmacology*
  • PPAR alpha / therapeutic use*
  • Plaque, Amyloid / drug therapy
  • Signal Transduction / drug effects

Substances

  • Neuroprotective Agents
  • PPAR alpha
  • Aspirin